Century Therapeutics

IPSC · NASDAQ

$1.64+$0.17 (+11.56%)TodayMarket closed · Oct 20, 7:30 PM ET

Prev close $1.47

Latest news

Press releaseOct 2, 8:05 AM ETGlobe Newswire
Century Therapeutics' CNTY-813 Demonstrates Continued Advancement Toward the Clinic Via Nonclinical Data Presented at EASD 2026
Press releaseSep 9, 4:05 PM ETGlobe Newswire
Century Therapeutics Appoints Joseph Truitt to Board of Directors
Press releaseAug 12, 8:00 AM ETGlobe Newswire
Century Therapeutics Reports Second Quarter 2026 Financial Results and Business Updates
Press releaseJul 9, 8:00 AM ETGlobe Newswire
Century Therapeutics Selected for Oral Presentations of CNTY-813 Preclinical Data at EASD 2026 and Breakthrough T1D® Clinical & Research Congress 2026
NewsJun 30, 8:03 AM ETAvi Kapoor
Concentrix Reports Downbeat Q2 Earnings, Joins Nuvectis Pharma, Vishay Intertechnology And Other Big Stocks Moving Lower In Tuesday’s Pre-Market Session
NewsJun 26, 10:18 AM ETAvi Kapoor
Apogee Enterprises Posts Strong Q1 Earnings, Joins ACADIA Pharmaceuticals, Crocs And Other Big Stocks Moving Higher On Friday
Press releaseJun 8, 4:05 PM ETGlobe Newswire
New CNTY-813 Preclinical Data Demonstrate Durable Glucose Control, Immune Evasion Under Alloimmune Pressure, and Scalable Manufacturing at ADA 2026
NewsJun 8, 8:04 AM ETAvi Kapoor
Graham, Appian And Other Big Stocks Moving Lower In Monday's Pre-Market Session
Press releaseJun 2, 9:02 AM ETPRNewswire
A Third Cancer Drug Just Entered the Clinic at an Under-$20-Million Company
NewsMay 27, 10:51 AM ETAvi Kapoor
Abercrombie & Fitch Upbeat Q1 Earnings, Joins Digital Turbine, Dycom Industries And Other Big Stocks Moving Higher On Wednesday
NewsMay 20, 8:05 AM ETAvi Kapoor
Lowe's, ZTO Express, Viavi Solutions And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
Press releaseMay 14, 8:00 AM ETGlobe Newswire
Corbus Pharmaceuticals Appoints Pharma Industry Veteran Brent Pfeiffenberger to Board of Directors
NewsMay 13, 8:20 AM ET
Century Therapeutics Q1 EPS $(0.11) Beats $(0.17) Estimate
Press releaseMay 13, 8:00 AM ETGlobe Newswire
Century Therapeutics Reports First Quarter Financial Results and Business Updates
Press releaseApr 30, 4:05 PM ETGlobe Newswire
Century Therapeutics Selected for Oral Presentation of CNTY‑813 Preclinical Data at the American Diabetes Association 86th Scientific Sessions
NewsApr 2, 5:05 PM ET
12 Health Care Stocks Moving In Thursday's After-Market Session
NewsApr 2, 8:05 AM ET
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Press releaseMar 12, 8:00 AM ETGlobe Newswire
Century Therapeutics Reports Full Year 2025 Financial Results and Business Updates
NewsFeb 26, 7:05 AM ET
12 Health Care Stocks Moving In Thursday's Pre-Market Session
NewsJan 8, 12:06 PM ET
12 Health Care Stocks Moving In Thursday's Intraday Session
NewsMar 21, 10:01 AM ET
Demystifying Century Therapeutics: Insights From 4 Analyst Reviews
NewsMar 19, 5:06 PM ET
12 Health Care Stocks Moving In Wednesday's After-Market Session
NewsMar 19, 4:02 PM ET
Century Therapeutics Shares Halted, News Pending
NewsJan 22, 8:00 AM ET
4 Analysts Have This To Say About Century Therapeutics
Press releaseDec 17, 2:00 PM ETBusiness Wire
Clear Street Launches Healthcare & Biotechnology Equity Research

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.

Latest news

Century Therapeutics' CNTY-813 Demonstrates Continued Advancement Toward the Clinic Via Nonclinical Data Presented at EASD 2026

Century Therapeutics Appoints Joseph Truitt to Board of Directors

Century Therapeutics Reports Second Quarter 2026 Financial Results and Business Updates

Century Therapeutics Selected for Oral Presentations of CNTY-813 Preclinical Data at EASD 2026 and Breakthrough T1D® Clinical & Research Congress 2026

Concentrix Reports Downbeat Q2 Earnings, Joins Nuvectis Pharma, Vishay Intertechnology And Other Big Stocks Moving Lower In Tuesday’s Pre-Market Session

Apogee Enterprises Posts Strong Q1 Earnings, Joins ACADIA Pharmaceuticals, Crocs And Other Big Stocks Moving Higher On Friday

New CNTY-813 Preclinical Data Demonstrate Durable Glucose Control, Immune Evasion Under Alloimmune Pressure, and Scalable Manufacturing at ADA 2026

Graham, Appian And Other Big Stocks Moving Lower In Monday's Pre-Market Session

A Third Cancer Drug Just Entered the Clinic at an Under-$20-Million Company

Abercrombie & Fitch Upbeat Q1 Earnings, Joins Digital Turbine, Dycom Industries And Other Big Stocks Moving Higher On Wednesday

Lowe's, ZTO Express, Viavi Solutions And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session

Corbus Pharmaceuticals Appoints Pharma Industry Veteran Brent Pfeiffenberger to Board of Directors

Century Therapeutics Q1 EPS $(0.11) Beats $(0.17) Estimate

Century Therapeutics Reports First Quarter Financial Results and Business Updates

Century Therapeutics Selected for Oral Presentation of CNTY‑813 Preclinical Data at the American Diabetes Association 86th Scientific Sessions

12 Health Care Stocks Moving In Thursday's After-Market Session

12 Health Care Stocks Moving In Thursday's Pre-Market Session

Century Therapeutics Reports Full Year 2025 Financial Results and Business Updates

12 Health Care Stocks Moving In Thursday's Pre-Market Session

12 Health Care Stocks Moving In Thursday's Intraday Session

Demystifying Century Therapeutics: Insights From 4 Analyst Reviews

12 Health Care Stocks Moving In Wednesday's After-Market Session

Century Therapeutics Shares Halted, News Pending

4 Analysts Have This To Say About Century Therapeutics

Clear Street Launches Healthcare & Biotechnology Equity Research